Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Deal Watch: Cancer Remains Hot Target At J.P. Morgan
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
More from Anticancer
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.